Methods: We used an oligo(dT)-coated manifold support to capture the mRNA directly from the cell lysate. After reverse transcription, the cDNA was eluted from the manifold support, and BCR-ABL and GAPDH mRNAs were quantified in real time using the TaqMan fluorogenic detection system. Results: The detection limit of the method was one positive K562 cell among 10 5 negative cells. GAPDH was chosen as a reference gene based on the low variation between samples from different stages of the disease and the low signal in the absence of reverse transcription. The day-to-day variation of the method (CV) was 32%. In 43 blood samples from 13 CML patients, mRNA quantification agreed well with cytogenetic data. Conclusions: The proposed procedure constitutes a reproducible and sensitive BCR-ABL mRNA quantification method and is suitable to monitor minimal residual disease in CML patients.
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Chimeric genes resulting from chromosomal translocations can be used as disease-specific markers for the malignant clone in several hematological malignancies (1 ) . Up to 90% of the patients with chronic myeloid leukemia (CML) 3 carry the cytogenetic abnormality known as the Philadelphia chromosome, which arises from a translocation between chromosomes 9 and 22 (2 ) . As a result, the 5Ј end of the BCR gene on chromosome 9 becomes fused to the 3Ј end of the ABL gene on chromosome 22 (3 ) . Cells carrying the translocation can be identified by cytogenetic analysis, fluorescence in situ hybridization, Southern blotting, or by reverse transcription-PCR (RT-PCR) of the fusion transcript [reviewed in Ref. (4 ) ]. Two predominant hybrid transcripts are observed in CML, joining either exon b2 or b3 of the BCR gene to exon 2 of the ABL gene. Quantitative competitive RT-PCR has been valuable for monitoring patients with CML after bone marrow transplantation (5) (6) (7) (8) . Consistently low or decreasing BCR-ABL mRNA expression constitutes a good prognostic factor. However, current RT-PCR-based technologies are difficult to implement in routine laboratories.
The advent of methods to monitor DNA amplification reactions in real time, such as the 5Ј-nuclease assay (9 ) , has made mRNA quantification by RT-PCR simpler and more accurate. The 5Ј-nuclease assay takes advantage of the 5Ј-nuclease activity of Taq DNA polymerase to cleave a dual-labeled probe hybridizing to the amplified fragment during the extension phase (10 ) . The cleavage reaction separates the two fluorophores, abolishing fluorescence resonance energy transfer, and producing increased fluorescence. The increase in fluorescence is proportional to the target accumulation and can be measured in real time (11 ) . The fractional amplification cycle at which fluorescence exceeds baseline fluorescence is called the threshold cycle (C T ). The C T value is recorded as a measure of the number of target molecules in the amplification reaction.
RNA typically is isolated through extraction with acid guanidinium-phenol-chloroform (12 ) , a method that is relatively labor-intensive and requires the use of hazardous chemicals. Simultaneous processing of numerous samples is difficult and time-consuming, limiting the applicability of RT-PCR in routine laboratories. We recently developed an oligo(dT)-coated manifold support that allows mRNA to be isolated directly from cell lysates by hybridization followed by transfer through the different washing and enzymatic steps of the assay with minimal pipetting (13 ) .
In the present report, we describe a streamlined and rapid method to quantify BCR-ABL transcripts, where the mRNA in cell lysates is captured onto a manifold solid support and quantified in real time using the TaqMan fluorogenic detection system. The whole procedure can be completed in a few hours. We used the method to follow BCR-ABL transcript expression in peripheral blood from 13 CML patients, comparing the results to cytogenetic data from bone marrow smears.
Materials and Methods patients and samples
We analyzed peripheral blood mononuclear cells from 13 patients with CML (Table 1) . Patients 1 and 2 received autologous stem cell transplantation (ASCT) during chronic phase, and the remaining patients received allogeneic bone marrow transplantation (BMT) during chronic phase.
After informed consent, peripheral blood was collected from CML patients in EDTA tubes, and mononuclear cells were separated by Ficoll density gradient centrifugation. The cells were washed in phosphate-buffered saline and counted. Viability was assessed by trypan blue exclusion.
Where indicated, erythrocytes were removed by lysis with NH 4 Cl, and the remaining cells were washed in phosphate-buffered saline before nucleated cells were lysed. Leukapheresis samples were collected from patients who had undergone ASCT, and were stored frozen. Cells were washed once in phosphate-buffered saline before lysis in extraction buffer.
The cell line K562, carrying the BCR-ABL translocation, was used as a positive control, and the lymphoblastoid cell line BSM was used as a negative control.
preparation of the oligo(dT)-coated manifold supports
The procedure has been described in detail elsewhere (13 ) . The manifold supports, shaped so that individual prongs fit the wells of a microtiter plate, were sonicated in 950 mL/L ethanol. Oligo(dT)-cellulose (Amersham Pharmacia Biotech) was rinsed repeatedly in triethylamine before being mixed with triethylamine to obtain a slurry. The manifold supports were immersed for 2 s in the slurry, washed once in ethanol and once in water, allowed to air dry, and stored at 4°C until used.
rna isolation and cDNA synthesis
Cells were counted and lysed in extraction buffer containing 100 mmol/L Tris-HCl (pH 7.9), 10 mmol/L EDTA, 5 mmol/L dithiothreitol, 500 mmol/L lithium chloride, and 10 g/L lithium dodecyl sulfate to a density of 10 7 cells/ mL. Viscosity was reduced by repeated passage through a needle (0.7 ϫ 50 mm). The manifold supports were presoaked in extraction buffer for 5 min and submerged in 50 L of cell lysate. mRNA was captured by hybridization to the supports on a shaking platform for 30 min at room temperature. The supports were subsequently washed eight times in 80 L of 10 mmol/L Tris-HCl (pH 7.5), 0.1 mol/L NaCl, and 1 mmol/L EDTA; transferred to fresh microtiter wells containing 50 L of 50 mmol/L Tris-HCl (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl 2 , 10 mmol/L dithiothreitol, 0.5 mmol/L dNTPs, 0.25 g/L bovine serum albumin, 2.5 mol/L random DNA hexamers (Pharmacia Biotech), 25 units of HPRI TM ribonuclease inhibitor (Amersham Life Science), and 200 U of M-MLV reverse transcriptase (Amersham Life Science); and incubated at 37°C for 1 h. The cDNA was eluted from the manifold support by denaturation at 95°C for 5 min in 50 L of water and amplified immediately or stored at Ϫ20°C.
primers and probes
Primers and 5Ј-nuclease probes were designed using Primer Express (PE Biosystems) software ( Table 2) . Two different forward primers were selected for the BCR-ABL transcript, one located in exon b2 and one located in exon b3 of the BCR gene. The 5Ј-nuclease probe was located in exon 2 of the ABL gene. The reference ␤-ACTIN cDNA was amplified with intron-spanning primers and the probe from the TaqMan ␤-ACTIN control reagent kit construction of the plasmid calibrators cDNA was prepared from a patient with a b2a2 translocation. BCR-ABL and GAPDH sequences were amplified with the described PCR primers. The amplification products were cloned into the pCRII vector (Invitrogen) and sequenced. Known amounts of each plasmid were linearized with HindIII and EcoRV, respectively. Serial dilutions (10-fold) representing 5 to 5 ϫ 10 5 copies of pCRBCR-ABL and 4 to 4 ϫ 10 5 copies of pCRGAPDH were prepared from the cleaved plasmids, aliquoted, and stored at Ϫ20°C.
measurement of bcr-abl mRNA in patient samples
Serial dilutions from 4 to 4 ϫ 10 5 copies of pCRGAPDH and 5 to 5 ϫ 10 5 copies of pCRb2a2 were amplified in duplicate. A calibration curve was derived by plotting the C T values obtained for each dilution against the logarithm of the plasmid copy number. The mean slopes of the calibration curves for the two genes were Ϫ3.42 for GAPDH and Ϫ3.6 for BCR-ABL, with interassay CVs of 6% and 4%, respectively. The calibration curves show a strong linear correlation, with correlation coefficients (r 2 ) between 0.97 and 0.997. BCR-ABL and GAPDH sequences were amplified in duplicate from the patient samples, and the copy numbers of both genes were calculated with help of the respective calibration curves. The estimated amount of BCR-ABL mRNA was normalized by dividing by the amount of GAPDH mRNA to compensate for variations in quantity or quality of starting mRNA as well as for differences in reverse transcriptase efficiency. The normalized values were multiplied by the constant 10 4 .
Because sample size and quality vary between individual samples, interpreting negative or weakly positive results may be difficult. We thus calculated the absolute limit of detection of BCR-ABL mRNA for each individual sample. The limit of detection was calculated by dividing the theoretically lowest number of BCR-ABL molecules detectable by PCR, i.e., one molecule, by the number of GAPDH molecules detected in that particular sample, and multiplying by 10 4 .
Results
We designed an efficient and accurate assay to monitor BCR-ABL mRNA expression in peripheral blood from CML patients. The different steps of the assay were validated with respect to the C T value obtained in the TaqMan assay and optimized for maximal sensitivity and reproducibility.
reproducibility of sample preparation
To determine the variability in binding capacity of the manifold supports and in the sample preparation procedure, mRNA from cell lysates was captured on individual prongs of different manifold supports. RNA from lysates corresponding to 2 ϫ 10 4 and 2 ϫ 10 5 K562 cells was immobilized on 6 and 10 individual prongs, respectively. After reverse transcription, the cDNA was amplified with primers and probes specific for GAPDH. Fig. 1 shows the individual C T values and the average of the C T values for the different RNA preparations. The SD of the C T value was 0.6 and 0.7 cycles for samples containing 2 ϫ 10 4 and 2 ϫ 10 5 cells, respectively.
sample handling
Successful amplification of RNA from blood samples required the elimination of the erythrocytes before cell lysis (data not shown). Erythrocytes were removed either by Ficoll separation or by hypotonic lysis with NH 4 Cl, and the remaining cells were counted in an hemocytometer before being lysed for RNA capture. Isolation of leukocytes from whole blood by Ficoll gradient centrifugation consistently gave a lower C T value than red cell lysis with hypotonic NH 4 Cl (Fig. 2) . In additional exper- b2a2  GCATTCCGCTGACCATCAATA  FAM-CAGCGGCCAGTAGCATCTGACTTTGA-TAMRA b  TCCAACGAGCGGCTTCAC  b3a2  CCACTGGATTTAAGCAGAGTTCAA  FAM-CAGCGGCCAGTAGCATCTGACTTTGA-TAMRA  TCCAACGAGCGGCTTCAC  GAPDH  GAAGGTGAAGGTCGGAGTC  JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA  GAAGATGGTGATGGGATTTC  BCR  TCTCCCTGACATCCGTGG  FAM-TGAAACTCCAGACTGTCCACAGCATTCC-TAMRA iments, mononuclear cells were purified from blood by Ficoll separation before mRNA isolation on the manifold supports.
sensitivity and specificity of the assay
To estimate the sensitivity of the method, K562 cells were mixed with variable numbers of cells from the BCR-ABLnegative lymphoblastoid cell line BSM to give ratios ranging from 1:1 to 1:10 6 . mRNA corresponding to 500 000 cells of the different dilutions was bound to the manifold supports and processed through the different steps of the assay. In 50% of the cases, BCR-ABL mRNA could be quantified in cDNA prepared from samples containing 1 K562 cell in 10 5 BSM cells. In the remaining 50% of the cases, only one of the duplicate samples of this dilution was positive for the dilution containing 1 K562 cell in 10 5 BSM cells. Both primer combinations (b2a2 and b3a2) gave the same detection limit (1 K562 cell in 10 5 BSM cells), and the slopes of the curves were very similar ( Fig. 3) . These results indicate that it is possible to use one primer/probe set to amplify either fusion variant.
No BCR-ABL products were obtained from cDNA prepared from BSM cells or mononuclear cells from healthy individuals or when reverse transcription was omitted.
choice of reference gene Three reference genes were investigated, ␤-ACTIN, GAPDH, and BCR in samples from 12 different individuals and two cell lines to determine which gene showed the smallest variability among samples and where genomic DNA contributed the least to the signal. All samples were processed in duplicate, and the reverse transcription enzyme was omitted in every second sample. All three genes could be amplified in the absence of the reverse transcription reaction. The C T values were on average 11 cycles higher in the case of ␤-ACTIN and GAPDH and 8 cycles in the case of BCR, compared with the corresponding samples treated with reverse transcriptase (Fig. 4) . Variations in reference gene expression among different individuals were very similar for the three genes tested, as shown by the similar SD values. In subsequent experiments, GAPDH was used as a reference gene.
day-to-day imprecision
The overall reproducibility of the quantification assay was estimated by analyzing six different samples, starting from the RNA isolation, on four different occasions. The expression of BCR-ABL and GAPDH mRNAs was calculated by comparison with their respective calibration curves, and the normalized BCR-ABL values were calculated. Fig. 5 shows the means and SDs for the different samples. The mean CV for the BCR-ABL/GAPDH ratio was 32% (range, 20 -44%).
analysis of transcript expression in patient samples
Lysates (50 L) from leukocytes obtained from patient blood samples were incubated with the manifold sup- K562 cells were mixed with the BCR-ABL-negative cell line BSM in different ratios. The cDNAs prepared from the individual mixes were amplified in duplicate with two different sets of primers, b2a2 and b3a2. The C T values were plotted against the different dilutions of K562 cells. ports and processed as described in Materials and Methods. Fig. 6 shows the BCR-ABL mRNA expression normalized to GAPDH mRNA expression for two different CML patients who received ␣-interferon (␣-IFN) ϩ hydroxyurea (HU) followed by ASCT. BCR-ABL mRNA expression in patient 1 decreased from 22 arbitrary units to below the detection limit after ASCT. The patient remained PCR-negative for 1 year after ASCT, with one transitional PCR-positive analysis in the 6 months follow-up sample. In an analysis 90 months after ASCT, BCR-ABL expression had increased to ϳ25 arbitrary units, although the patient remained in clinical and cytogenetic remission. Patient 2 did not respond clinically to ASCT. The increases in both normalized BCR-ABL mRNA expression and numbers of Philadelphia-positive cells also reflect this fact.
The rest of the patients received allogeneic BMT, patients 3-6 from an unrelated donor and patients 7-13 from a relative. In this group of patients, a pretransplantation sample was available for patients 4, 5, and 6. The normalized BCR-ABL mRNA expression at diagnosis was on average 805 arbitrary units (range, 230 -3200; Fig. 7 ). After BMT, BCR-ABL mRNA expression dropped dramatically, between 1000-and 10 000-fold, over a period of 3-6 months and became undetectable in patient 5, 3 months after BMT (Fig. 7) , and in patient 6, 9 months after BMT (Fig. 7) . In three additional patients analyzed 30 -48 months after BMT, the normalized BCR-ABL mRNA expression was below the detection limit (data not shown). After allogeneic BMT (6 -12 months), BCR-ABL mRNA expression was always below 5 arbitrary units. The patients receiving allogeneic BMT remained in hematological and cytogenetic remission during the period studied, except patients 7 and 10. Both patients were transiently Philadelphia chromosome positive (1 cell in 50) in a bone marrow sample 12 and 24 months after BMT, respectively.
Discussion
In the present report, we describe a reliable and sensitive method to monitor patients with CML by measuring BCR-ABL mRNA in peripheral blood. The method is suitable to follow CML patients after BMT.
We propose a streamlined RNA isolation method where poly(A)ϩ mRNA is isolated directly from the cell lysate by binding to an oligo(dT)-coated manifold support. Manifold supports are devices composed of sets of prongs that project into a corresponding set of reaction wells. The surfaces of the prongs may be modified to allow the binding of biomolecules so that these can be processed in a set of reactions and loaded on detection instruments.
The use of manifold supports in molecular diagnostics has been useful for genotyping by the oligonucleotide ligation assay or minisequencing, and for the detection of mutations by sequencing [reviewed in Ref. (14 ) ]. Because the RNA binds to a solid support, multiple samples can be manipulated in parallel with minimal effort. Moreover, the reduction in the number of sample processing and pipetting steps diminishes the risk for uncontrolled variables associated with the quality of the RNA. Currently, instability of RNA limits the use of RT-PCR to research laboratories with trained personnel. The use of manifold supports greatly simplifies mRNA isolation, making RT-PCR-based analysis more accessible to routine laboratories. The method can also be adapted to other oligo(dT)coated solid supports, such as paramagnetic beads. We found that 25 L of Dynabeads (Dynal) had a binding capacity similar to that of individual prongs in our manifold support (data not shown).
Both ␤-ACTIN and GAPDH are known to have pseudogenes that can give rise to a PCR product that interferes with the quantification of these RNAs. The presence of genomic DNA in the RNA preparation thus represents a potential source of error when quantifying the reference gene. The difference in C T values (11 cycles) that we found between the samples amplified with and without reverse transcriptase shows that genomic DNA contamination of the mRNA bound to the manifold support is negligible.
We found that a single primer/probe set was adequate to amplify the two most common BCR-ABL fusion variants, which simplifies the assay and eliminates the need to analyze the fusion variant of individual patients. This result is in agreement with two recent reports where all fusion variants of BCR-ABL could be quantified using a single set of primers (15, 16 ) .
We also examined how sample preparation affected the sensitivity of the assay. It was necessary to remove erythrocytes to obtain a positive PCR, probably because of the known inhibitory effect of hemoglobin (17 ) . Peripheral blood mononuclear cell purification by Ficoll density separation gave lower C T values for both BCR-ABL and GAPDH mRNAs, presumably because of better RNA quality.
Because clinical specimens are collected remote from the site of analysis, differences in time from sample collection to RNA isolation may lead to variable degradation of RNA in the sample, with variability in assay sensitivity as a consequence. We calculated the absolute detection limit of every sample, defined as one single copy of BCR-ABL divided by the number of copies of GAPDH for a particular sample, multiplied by the constant 10 4 . This value should constitute a valuable help in interpreting results by reflecting the size and quality of the sample. The absence of BCR-ABL amplification can only be interpreted as a true negative when amplification of the reference gene reveals a positive result. In addition, positive samples where the normalized BCR-ABL mRNA expression falls below the detection limit are to be interpreted with caution.
The interassay imprecision (CV) was low (4 -6%) for calibrators but high for patient samples (mean, 32%). This implies that the precision of the present method is insufficient to analyze small differences in BCR-ABL mRNA expression between samples.
The normalized BCR-ABL expression measurements from 13 CML patients correlated well with clinical and cytogenetic data. Recently, several groups have reported analysis of CML patients using real-time RT-PCR (15, 18 -20 ) and found that real-time PCR was suitable for following the kinetics of BCR-ABL mRNA in CML. The sensitivity of our method is comparable to that of Preudhomme et al. (20 ) and Eder et al. (19 ) , indicating that the manifold support has sufficient capacity to monitor minimal residual disease, where only a small minority of the cells are positive for BCR-ABL fusion mRNA.
Typically, the normalized BCR-ABL values for untreated patients were between 250 and 1000 arbitrary units. Patients that show a partial response (␣-IFN ϩ HU and ASCT) had BCR-ABL values between 100 and 10 arbitrary units. After allogeneic BMT, BCR-ABL mRNA fell dramatically to Ͻ5 arbitrary units. Additional studies will be necessary to determine what threshold BCR-ABL mRNA expression is critical and predictive of relapse.
In conclusion, the combination of a manifold support to isolate mRNA in a fast and reproducible manner, together with the advantages of real-time RT-PCR is promising as a sensitive and accurate method to study the kinetics of BCR-ABL mRNA expression, and is suitable to monitor minimal residual disease in CML patients.
